AI Terminal
Cannovum Cannabis AG
Regulatory Filings • Nov 28, 2022
7293_rns_2022-11-28_1e27b389-3c64-4fcd-87df-fb0a518aa2bf.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 28 November 2022 08:30
Cannovum AG shares move Dec. 1st 2022 to primary market of Düsseldorf Stock Exchange
EQS-News: Cannovum AG / Key word(s): Miscellaneous
Cannovum AG shares move Dec. 1st 2022 to primary market of Düsseldorf Stock Exchange
28.11.2022 / 08:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
Berlin, 28.11.2022 – Cannovum AG (Düsseldorf, Munich, Hamburg, Berlin stock exchanges, gettex: ISIN DE000A2LQU21), the first German fully licensed cannabis company on the stock exchange, will move on Dec. 1st 2022 from the Open Market to the “Primary Market” segment of the Düsseldorf Stock Exchange. With this move, the company commits to higher transparency standards and underlines its commitment to quality in its communication with investors.
“We are very pleased to be represented with our share in the primary market,” says Pia Marten, board member and co-founder of Cannovum AG. “The change is an important step for us as a growth company. This demonstrates our claim as a market leader in the upcoming legal cannabis segment. This emerging market will account for well over 8 billion euros in sales per year in Germany alone.”
Contact:
Klaus Madzia,CMO + IR, Cannovum AG
Phone +49 30 3982 163 62, [email protected]
Cannovum AG is the first German fully licensed cannabis company to be listed on the stock exchange. The shares are traded on the stock exchanges of Düsseldorf, Munich, Berlin, Hamburg and gettex. Cannovum AG is ready for the legalization of cannabis and optimally prepared for the coming 8 billion market: both for sales via pharmacies and via licensed specialty stores and online shipping. Already today, Cannovum AG is a market leader in the medical cannabis sector.
Through its subsidiary Cannovum Health eG, it is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the importation of high-quality cannabinoid precursors, medical-scientific education and nationwide distribution for simplified and equitable access to cannabis-based therapies.
For more information, visit www.cannovum.de
28.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Cannovum AG |
| Rheinsberger Str. 76/77 | |
| 10115 Berlin | |
| Germany | |
| Phone: | +49 (0)30 3982 16360 |
| E-mail: | [email protected] |
| Internet: | www.cannovum.com |
| ISIN: | DE000A2LQU21 |
| WKN: | A2LQU2 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich |
| EQS News ID: | 1498219 |
| End of News | EQS News Service |